FerroKin BioSciences Announces Start of a Phase 2 Clinical Trial of FBS0701 as a Novel Treatment for Transfusional Iron Overload
September 09, 2010 13:32 ET | FerroKin BioSciences
SAN FRANCISCO, Sept. 9, 2010 (GLOBE NEWSWIRE) -- FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for...
FerroKin BioSciences Completes $12 Million Financing
June 17, 2010 11:55 ET | FerroKin BioSciences
SAN FRANCISCO, June 17, 2010 (GLOBE NEWSWIRE) -- FerroKin BioSciences, a biotechnology company developing a new therapy for the treatment of iron overload, today announced the closing of a $12 million...